{
  "drug_name": "Ceftizoxime",
  "tradename": "Cefizox",
  "usage_and_dosing": {
    "general": [
      "Ceftizoxime is a 3rd generation parenteral cephalosporin with in vitro activity against aerobic gram-positive cocci (but not MRSA or enterococci) and aerobic gram-negative bacilli (but not P. aeruginosa) and selected anaerobic bacteria (but not B. fragilis).",
      "Inactivated by bacteria that produce extended spectrum beta-lactamases (ESBLs).",
      "Major adverse effects are allergy and development of C. difficile toxin-mediated colitis. For class-wide adverse effects, see Cephalosporins, Overview."
    ],
    "adult_dose": {
      "usual_dose": "1-2 gm IV q8-12h",
      "life_threatening_infection": "Max 2 gm IV q4h (or 4 gm IV q8h)"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "150-200 mg/kg/day (divided q6-8h)",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "1.7",
    "half_life_esrd": "15-35",
    "dose_renal_function_normal": "2 gm IV q8h",
    "crcl_or_egfr": "CrCl >90: No dosage adjustment. CrCl >50-90: 2 gm q8-12h. CrCl 10-50: 2 gm q12-24h. CrCl <10: 2 gm q24h",
    "hemodialysis": "2 gm q24h (+ extra 1 gm AD)",
    "capd": "0.5-1 gm q24h",
    "crrt": "2 gm q12-24h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No data",
    "moderate_impairment_child_pugh_b": "No data",
    "severe_impairment_child_pugh_c": "No data"
  },
  "adverse_effects": [
    "Local phlebitis (4%), fever, rash (2%), neutropenia, eosinophilia (4%), thrombocytopenia, increased PT/PTT, C. difficile colitis, increased LFTs (4%).",
    "Ceftizoxime has the same R1 side chain as cefotaxime, cefpodoxime, cefpirome, cefditoren, ceftriaxone, and cefepime. Cross-allergenicity may occur."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "60 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "30",
    "volume_of_distribution_vd_l_kg": "0.34 L/kg",
    "avg_serum_half_life_hr": "1.7",
    "elimination": "Renal",
    "bile_penetration_percent": "34-82",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "85 (1 gm IV, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": ["OAT1", "OAT3"],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
    "No significant interactions"
  ],
  "comments": [
    "Where available. No longer marketed in the US"
  ]
}
